RxDoctor Payments Data

Gregory Mumm, MD

Rheumatology · Sioux Falls, SDNPI 1548228810

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Amgen at 30.7% of the total. 2025 is the largest year on record at $291, 5.9 times the $49 reported in 2019.

$599in general payments, 2019–2025

Across 25 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$184
  • AbbVie$168
  • Pfizer$87
  • Sandoz$52
  • E.r. Squibb & Sons, L.L.C.$49
  • UCB, Inc.$25
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few rheumatology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$88,595
Medicare patients
533
Services billed
1,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab118$830,033
Enbrel SureclickEtanercept75$563,872
Xeljanz XrTofacitinib Citrate75$479,575
RinvoqUpadacitinib25$197,909
Cosentyx Sensoready (2 Pens)Secukinumab22$157,125
OrenciaAbatacept13$129,282
KevzaraSarilumab25$96,026
EnbrelEtanercept11$76,979
Cimzia (2 Pack)Certolizumab Pegol12$64,512
TymlosAbaloparatide12$28,304
MethotrexateMethotrexate Sodium909$24,777
Leflunomide259$19,875
Adalimumab-Aacf(Cf) Pen (2 Pk)Adalimumab-Aacf18$15,828
Hydroxychloroquine Sulfate563$15,652
Hadlima(Cf) PushtouchAdalimumab-Bwwd11$10,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$168$197,90925 claims
E.r. Squibb & Sons, L.L.C.Orencia$49$129,28213 claims
AmgenEnbrel$184$76,97911 claims
UCB, Inc.Cimzia (2 Pack)$25$64,51212 claims
Radius Health, Inc.Tymlos$16$28,30412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other rheumatology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →